Postoperative adjuvant chemotherapy with cisplatin, etoposide, and pirarubicin for endometrial carcinoma patients with lymph node metastasis: A pilotstudy

We evaluated the effects of a combined chemotherapy regimen on endometrial carcinoma in 14 patients with lymph node metastasis. After surgery, the pat ients were treated with 3 cycles of chemotherapy (PVP regimen) every 4 week s. The PVP regimen consisted of 75 mg/m(2) cisplatin on day 1, 40 mg/m(2) p irarubicin (P) on day 1, and 75 mg/m(2) etoposide (VP-16: V) on days 2, 3 a nd 4. The effect of adjuvant chemotherapy was evaluated based on progressio n-free survival (PFS), overall survival (OS), and adverse effects. The 5-ye ar PFS rate was 52% [95% confidence interval (CI), 10-94%], and the 5-year OS rate was 50% (95% CI, 16-84%). The major toxicity was myelosuppression. One hundred percent of patients had neutropenia above grade 3, but all reco vered from myelosuppression. PVP therapy may be an effective adjuvant thera py for endometrial carcinoma patients with lymph node metastasis used as an alternative to radiation therapy.